GRIFOLS | GRF - Operating Expenses


GRIFOLS reported EUR1.45B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alcon AG USD 2.41B 4M Mar/2026
Almirall EUR 517.4M 32K Dec/2025
Amadeus IT EUR 1.19B 91.3M Mar/2026
Amarin USD 51.48M 113K Dec/2025
argenx SE USD 904M 10.57M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Cie Automotive EUR 1.69B 20.74M Dec/2025
Demant DKK 9.63B 241M Dec/2025
Ence Energia y Celulosa EUR 188.7M 35.73M Mar/2026
Essilor EUR 13.09B 1.07B Dec/2025
Ferrovial EUR 4.62B 584M Dec/2025
Fresenius EUR 5.25B 337M Dec/2025
Fresenius Medical Care EUR 4.34B 63M Mar/2026
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
GRIFOLS EUR 1.45B 255.28M Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Inditex EUR 6.99B 2.64B Mar/2026
Lakefront Biotherapeutics EUR 70.18M 50.08M Mar/2026
Merck EUR 4.09B 687M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Philips EUR 3.6B 775M Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
Smith & Nephew USD 2.52B 84M Dec/2025
UCB EUR 2.96B 196M Dec/2025
Viscofan EUR 262.6M 2.21M Mar/2026